tasly sants

   Company focus on chemical medicine production, mainly for oral solid dosage form (tablets and hard capsules). The existing annual production capacity can reach to 650 million unit supplying domestic and oversea markets.  It is expected to reach 2.1 billion unit chemicals dosage in the future.

   There are four formulation production lines, three packaging lines and one API production workshop in the company. Company has passed UK MHRA GMP inspection in 2010, west Africa Burkina Faso GMP inspection in 2012, China 2010 version GMP inspection in 2014, and get Australian TGA GMP certification in 2014.

  Plant must be flexible and responsive to cope with rapidly changing mark conditions.

•Dosage form 

•Hard capsule

•Tablet (Film Coated tablet)

•Categories

•Non-antibiotic product 

•Non-potent or high sensitized product 

•Non- hormones product

•Package Form 

•PVC/PVDC-Aluminum blister

•Aluminum-PVC/PVDC-Aluminum blister 

•Bottle line

•Aluminum-PVC/PVDC-Aluminum blister